0800 Immune

0800 466 863

Journal article

Pertussis and influenza immunisation coverage of pregnant women in New Zealand

Background: Immunisation is an important public health policy and measuring coverage is imperative to
identify gaps and monitor trends. New Zealand (NZ), like many countries, does not routinely publish coverage
of immunisations given during pregnancy. Therefore, this study examined pregnancy immunisation
coverage of all pregnant NZ women between 2013 and 2018, and what factors affected uptake.
Methods: A retrospective cohort study of pregnant women who delivered between 2013 and 2018 was

Age is not just a number - synopsis of the 5th New Zealand Influenza Symposium 2019

Summary

This paper is a summary of the 5th New Zealand Influenza Symposium run by the Immunisation Advisory Centre in collaboration with the Ministry of Health. National and international presenters discussed improving the uptake of the influenza vaccine in New Zealand, and the severity and consequences of influenza, particularly for the elderly and those with chronic health issues. Highlighted were the benefits of influenza vaccination and how it can reduce declines in cognitive and physical health that can lead to loss of independence for older people.

A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero

We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age.

Influences and policies that affect immunisation coverage - a summary review of literature

Effective national immunisation programmes require a high proportion of the population to be immunised. Although New Zealand has made significant progress towards immunisation goals over the last two decades, immunisation coverage remains inadequate to prevent intermittent outbreaks of disease and immunisation inequities persist between geographic, ethnic and socioeconomic groups.

Vaccine-Preventable Disease-Associated Hospitalisations Among Migrant and Non-migrant Children in New Zealand

Migrants may experience a higher burden of vaccine-preventable disease (VPD)-associated hospitalisations compared to the host population. A retrospective cohort study from 2006 to 2015 was conducted that linked de-identified data from government sources using Statistic NZ’s Integrated Data Infrastructure. VPD-related hospitalisations were compared between three cohorts of children from birth to 5 years old: foreign-born children who migrated to NZ, children born in NZ of recent migrant mothers, and a comparator group of children born in NZ without a recent migration background.

No live vaccines for people being treated with leflunomide [letter]

Vaccination with live vaccines, such as the live herpes zoster vaccine, is not recommended for people being treated with leflunomide, nor should a live vaccine be given sooner than a period of at least 6 months has elapsed after stopping leflunomide. Leflunomide has a long half‐life. There are no clinical data on the safety of vaccination with live vaccines during treatment with leflunomide.

100 years since the 1918 influenza pandemic— progress made, yet questions remain. A synopsis of the 4th New Zealand Influenza Symposium, February 2018

The year 2018 marks 100 years since the 1918 influenza pandemic that caused devastating social and
economic destruction worldwide. Despite substantial progress made with influenza research and strategies
to control disease outbreaks, influenza continues to be a global public health problem. This paper presents
a synopsis of the 4th New Zealand Influenza Symposium hosted by the Immunisation Advisory Centre in
February 2018. During this symposium, international and national experts and service providers convened to

Pneumococcal conjugate vaccines turning the tide on inequity - a retrospective cohort study of New Zealand children born 2006-2015

Background

Hospitalization rates for infectious diseases in New Zealand (NZ) children have increased since 1989. The highest burden is among Māori and Pacific children, and the most socioeconomically deprived. NZ introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV10 in 2011 and PCV13 in 2014.

Methods

Exploring immunisation inequities among migrant and refugee children in New Zealand

Migrants may experience immunisation inequities compared with the host population related to barriers with accessing immunisations in their home countries, while migrating and/or post-arrival. This retrospective cohort study explored vaccination rates among migrant and non-migrant children in New Zealand (NZ). Linked de-identified data from various government sources from 1 January 2006 to 31 December 2015 were analysed using Statistic NZ’s Integrated Data Infrastructure.